The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Abstract
A MESSAGE FROM ASCO'S PRESIDENT Since its founding in 1964, the American Society of Clinical Oncology (ASCO) has been committed to improving cancer outcomes through research and the delivery of quality care. Research is the bedrock of discovering better treatments—providing hope to the millions of individuals who face a cancer diagnosis each year. The studies featured in “Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology” represent the invaluable contributions of thousands of patients who participate in clinical trials and the scientists who conduct basic and clinical research. The insights described in this report, such as how cancers hide from the immune system and why cancers may become resistant to targeted drugs, enable us to envision a future in which cancer will be even more controllable and preventable. The scientific process is thoughtful, deliberate, and sometimes slow, but each advance, while helping patients, now also points toward new research questions and unexplored opportunities. Both dramatic and subtle breakthroughs occur so that progress against cancer typically builds over many years. Success requires vision, persistence, and a long-term commitment to supporting cancer research and training. Our nation's longstanding investment in federally funded cancer research has contributed significantly to a growing array of effective new treatments and a much deeper understanding of the drivers of cancer. But despite this progress, our position as a world leader in advancing medical knowledge and our ability to attract the most promising and talented investigators are now threatened by an acute problem: Federal funding for cancer research has steadily eroded over the past decade, and only 15% of the ever-shrinking budget is actually spent on clinical trials. This dismal reality threatens the pace of progress against cancer and undermines our ability to address the continuing needs of our patients. Despite this extremely challenging economic environment, we continue to make progress. Maintaining and accelerating that progress require that we keep our eyes on the future and pursue a path that builds on the stunning successes of the past. We must continue to show our policymakers the successes in cancer survival and quality of life (QOL) they have enabled, emphasizing the need to sustain our national investment in the remarkably productive US cancer research enterprise. We must also look to innovative methods for transforming how we care for—and learn from—patients with cancer. Consider, for example, that fewer than 5% of adult patients with cancer currently participate in clinical trials. What if we were able to draw lessons from the other 95%? This possibility led ASCO this year to launch CancerLinQ, a groundbreaking health information technology initiative that will provide physicians with access to vast quantities of clinical data about real-world patients and help achieve higher quality, higher value cancer care. As you read the following pages, I hope our collective progress against cancer over the past year inspires you. More importantly, I hope the pride you feel motivates you to help us accelerate the pace of scientific advancement. Clifford A. Hudis, MD, FACP President American Society of Clinical Oncology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., Ferrell, B. R., Loscalzo, M., Meier, D. E., Paice, J. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5161 · Cited by 1,319
Self-citationBenefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach, P. B., Mirkin, J. N., Oliver, T. K., Azzoli, C. G., Berry, D. A., Brawley, O. W., Byers, T., Colditz, G. A., Gould, M. K., Jett, J. R., et al. (2012) · JAMA · doi:10.1001/jama.2012.5521 · Cited by 1,244
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Patients’ expectations about effects of chemotherapy for advanced cancer
Weeks, J. C., Catalano, P. J., Cronin, A., Finkelman, M. D., Mack, J. W., Keating, N. L., & Schrag, D. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204410 · Cited by 1,149 · cited 1×
“A study involving more than 1,000 patients nationally, as part of CanCORS (Cancer Care Outcomes Research and Surveillance), found that approximately 70% of patients with lung cancer and 80% of patients with colorectal cancer did not understand that they had incurable disease and that the goal of treatment was palliati…”
BackgroundResults of Initial Low-Dose Computed Tomographic Screening for Lung Cancer
The National Lung Screening Trial Research Team (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209120 · Cited by 1,088
Jemal, A., Simard, E. P., Dorell, C., Noone, A.-M., Markowitz, L. E., Kohler, B., Eheman, C., Saraiya, M., Bandi, P., Saslow, D., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs491 · Cited by 993
Genomic Analysis of Non- NF2 Meningiomas Reveals Mutations in TRAF7 , KLF4 , AKT1 , and SMO
Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Özduman, K., Avşar, T., Li, J., Murray, P. B., Henegariu, O., et al. (2013) · Science · doi:10.1126/science.1233009 · Cited by 912
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Maxson, J. E., Gotlib, J., Pollyea, D. A., Fleischman, A. G., Agarwal, A., Eide, C. A., Bottomly, D., Wilmot, B., McWeeney, S. K., Tognon, C. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214514 · Cited by 571
Humphrey, L. L., Deffebach, M., Pappas, M., Baumann, C., Artis, K., Mitchell, J. P., Zakher, B., Fu, R., & Slatore, C. G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-6-201309170-00690 · Cited by 534
Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture
de Lima, M., McNiece, I., Robinson, S. N., Munsell, M., Eapen, M., Horowitz, M., Alousi, A., Saliba, R., McMannis, J. D., Kaur, I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207285 · Cited by 475
Self-citationSmith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0494 · Cited by 446
Self-citationFarley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., Paietta, E., Racevskis, J., Rowe, J. M., Tallman, M. S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3078 · Cited by 350
Smith, A. W., Bellizzi, K. M., Keegan, T. H. M., Zebrack, B., Chen, V. W., Neale, A. V., Hamilton, A. S., Shnorhavorian, M., & Lynch, C. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3173 · Cited by 337
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia
Meyer, J. A., Wang, J., Hogan, L. E., Yang, J. J., Dandekar, S., Patel, J. P., Tang, Z., Zumbo, P., Li, S., Zavadil, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2558 · Cited by 297
Self-citationLong-Term Survival of Participants in the Prostate Cancer Prevention Trial
Thompson, I. M., Goodman, P. J., Tangen, C. M., Parnes, H. L., Minasian, L. M., Godley, P. A., Lucia, M. S., & Ford, L. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215932 · Cited by 288
Self-citationGaziano, J. M., Sesso, H. D., Christen, W. G., Bubes, V., Smith, J. P., MacFadyen, J., Schvartz, M., Manson, J. E., Glynn, R. J., & Buring, J. E. (2012) · JAMA · doi:10.1001/jama.2012.14641 · Cited by 269
Sundi, D., Ross, A. E., Humphreys, E. B., Han, M., Partin, A. W., Carter, H. B., & Schaeffer, E. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.0302 · Cited by 233
Eliminating racial disparities in colorectal cancer in the real world: It took a village
Grubbs, S. S., Polite, B. N., Carney, J., Bowser, W., Rogers, J., Katurakes, N., Hess, P., & Paskett, E. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.8412 · Cited by 201
Hamid, O., Sosman, J. A., Lawrence, D. P., Sullivan, R. J., Ibrahim, N., Kluger, H. M., Boasberg, P. D., Flaherty, K., Hwu, P., Ballinger, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.9010 · Cited by 170
Lunardi, A., Ala, U., Epping, M. T., Salmena, L., Clohessy, J. G., Webster, K. A., Wang, G., Roberta Mazzucchelli, A., Bianconi, M., Stack, E. C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2650 · Cited by 152
Conti, R. M., Bernstein, A., Villaflor, V. M., Schilsky, R. L., Rosenthal, M. B., & Bach, P. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7252 · Cited by 127
Wright, J. D., Neugut, A. I., Ananth, C. V., Lewin, S. N., Wilde, E. T., Lu, Y., Herzog, T. J., & Hershman, D. L. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2921 · Cited by 124
Barlési, F., Blons, H., Beau‐Faller, M., Rouquette, I., Ouafik, L., Mosser, J., Merlio, J., Bringuier, P. P., Jonveaux, P., Maréchal, C. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8000 · Cited by 117
Planchard, D., Mazières, J., Riely, G. J., Rudin, C. M., Barlési, F., Quoix, É., Souquet, P. J., Socinski, M. A., Switzky, J. C., Ma, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8009 · Cited by 109
Ng, A. K., Garber, J. E., Diller, L., Birdwell, R. L., Feng, Y., Neuberg, D. S., Silver, B., Fisher, D. C., Marcus, K. J., & Mauch, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5732 · Cited by 108
Paskett, E. D., Katz, M. L., Post, D. M., Pennell, M. L., Young, G. S., Seiber, E. E., Harrop, J. P., DeGraffinreid, C. R., Tatum, C. M., Dean, J. A., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0523 · Cited by 101
Gray, R. G., Rea, D. W., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., Poole, C. J., Bates, T., Chetiyawardana, S., Dewar, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.5 · Cited by 98
Cho, D. C., Sosman, J. A., Sznol, M., Gordon, M. S., Hollebecque, A., Hamid, O., McDermott, D. F., Delord, J., Rhee, I. P., Mokatrin, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4505 · Cited by 97
Lee, R. J., Saylor, P. J., Michaelson, M. D., Rothenberg, S. M., Smas, M. E., Miyamoto, D. T., Gurski, C., Xie, W., Maheswaran, S., Haber, D. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0319 · Cited by 73
Brose, M. S., Nutting, C. M., Jarząb, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4 · Cited by 70
Self-citationMack, J. W., Chen, K., Boscoe, F. P., Gesten, F. C., Roohan, P. J., Weeks, J. C., Schymura, M. J., & Schrag, D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9271 · Cited by 66
Ou, S. I., Bang, Y., Camidge, D. R., Riely, G. J., Salgia, R., Shapiro, G. I., Solomon, B., Engelman, J. A., Kwak, E. L., Clark, J. W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8032 · Cited by 62
Johnson, B. E., Kris, M. G., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Wistuba, I. I., Franklin, W. A., Ladanyi, M., Su, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8019 · Cited by 60
Self-citationSznol, M., Kluger, H. M., Hodi, F. S., McDermott, D. F., Carvajal, R. D., Lawrence, D. P., Topalian, S. L., Atkins, M. B., Powderly, J. D., Sharfman, W. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.cra9006 · Cited by 58
Fukutomi, A., Uesaka, K., Boku, N., Kanemoto, H., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4008 · Cited by 51
Tewari, K. S., Sill, M. W., Long, H. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3 · Cited by 48
Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival
Gamazon, E. R., Pinto, N. R., Konkashbaev, A. I., Im, H. K., Diskin, S. J., London, W. B., Maris, J. M., Dolan, M. E., Cox, N. J., & Cohn, S. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs503 · Cited by 41
Shastri, S. S., Mittra, I., Mishra, G. A., Gupta, S. D., Dikshit, R. P., & Badwe, R. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2 · Cited by 33
Sosman, J. A., DAUD, A. I., Weber, J. S., Kim, K., Kefford, R. F., Flaherty, K. T., Infante, J. R., Hamid, O., Cebon, J. S., Schuchter, L. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.9005 · Cited by 26
Beyond Jeopardy!: Harnessing IBM's Watson to improve oncology decision making.
Bach, P. B., Zauderer, M. G., Gucalp, A., Epstein, A. S., Norton, L., Seidman, A. D., Caroline, A., Grigorenko, A., Bartashnik, A., Wagner, I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.6508 · Cited by 7
Self-citation
Cited by
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Diversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
Manzoni, C., Kia, D. A., Vandrovcova, J., Hardy, J., Wood, N. W., Lewis, P. A., & Ferrari, R. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbw114 · Cited by 804
Causes of death among cancer patients
Zaorsky, N. G., Churilla, T. M., Egleston, B. L., Fisher, S. G., Ridge, J. A., Horwitz, E. M., & Meyer, J. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw604 · Cited by 657
Metadata
- Authors
- Patel, J. D., Krilov, L., Adams, S., Aghajanian, C., Basch, E., Brose, M. S., Carroll, W. L., de Lima, M., Gilbert, M. R., Kris, M. G., Marshall, J. L., Masters, G. A., O'Day, S. J., Polite, B., Schwartz, G. K., Sharma, S., Thompson, I., Vogelzang, N. J., & Roth, B. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-01-10
- Volume
- 32
- Issue
- 2
- Pages
- 129-160
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125146087
- Cited by
- 434
- References
- 66
- FWCI
- 43.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.